Advertisement

Urinzytologie pp 171-184 | Cite as

Immunzytologie bei Urotheltumoren

  • B. J. Schmitz-Dräger

Zusammenfassung

Prinzipiell ist der Urin ein ideales Medium zum Nachweis von Urotheltumoren. Dies beruht zum einen auf dem exklusiven Kontakt des Urins mit den ableitenden Harnwegen; die Kontaktdauer zwischen Tumor und Urin kann bis zu mehreren Stunden betragen. Weitere Vorteile liegen darin, daß die Gewinnung einer Probe auf nichtinvasivem Wege erfolgen kann und praktisch unbegrenzte Mengen gewonnen werden können. Urinzytologie und Durchflußzytometrie sind Techniken, die die Vorzüge dieses Mediums nutzen. Vor allem die Urinzytologie hat sich in den vergangenen Jahren in der klinischen Routine bewährt und bildet, neben der Zysturethroskopie, die zweite Säule in der Diagnostik des Transitionalzellkarzinoms (TCC).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arndt R, Dürkopf H, Huland H, Donn F, Loening T, Kalthoff H (1987) Monoclonal antibodies for characterization of the heterogeneity of normal and malignant transitional cells. J Urol 137: 758–763PubMedGoogle Scholar
  2. Bander NH (1987) Monoclonal antibodies: State of art. J Urol 137: 603–612PubMedGoogle Scholar
  3. Chicheportiche C, Gazarossian E, Longin, A, Lebreuil G, Hermanowicz M, Richaud C, Beley S, Kaphan S, Fontaniére B, Cotte G, Laurent J-C (1993) Combination of standard cytology and immuncytology with BL2–10D1 monoclonal antibody for monitoring-treated bladder cancer patients. Eur Urol 23: 405–408PubMedGoogle Scholar
  4. Chopin DK, deKernion JB, Rosenthal DL, Fahey JL (1985) Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing. J Urol 134: 260–265PubMedGoogle Scholar
  5. Cordon-Cardo C, Reuter VE, Lloyd KO, Sheinfeld J, Fair WR, Old LJ, Melamed MR (1988) Blood group-related antigens in human urothelium: enhanced expression of precursor, Lex and Ley determinants in urothelial carcinoma. Cancer Res 48: 4113–4118PubMedGoogle Scholar
  6. Decken K, Schmitz-Dräger BJ, Rohde D, Nakamura S, Ebert T, Ackermann R (1992) Monoclonal antibody Due ABC3 directed against transitional cell carcinoma. I. Production, specificity analysis and preliminary characterization of the antigen. J Urol 147: 235–241PubMedGoogle Scholar
  7. Decken K, Held P, Shibayama T, Nakamura S, Ebert T, Schmitz-Dräger B (1994) Monoclonal antibodies directed against urothelial differentiation antigens, (submitted)Google Scholar
  8. Dubernard JM, Devonec M, Amiel J, Bouvier R, Fontaniere B, Faucon M (1982) Correlation between cytology and cystoscopy in the follow-up of patients with bladder tumors. Eur Urol 8: 5–8PubMedGoogle Scholar
  9. Grossman HB (1983) Hybridoma antibodies reactive with human bladder carcinoma cell surface antigens. J Urol 130: 610–614PubMedGoogle Scholar
  10. Hijazi A, Devonec M, Bouvier R, Revillard J-P (1989) Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonucleic acid content in human bladder tumors. J Urol 141: 522–526PubMedGoogle Scholar
  11. Huland E, Huland H, Arndt R, Baisch H, Klöppel G (1988) Urindiagnostik oberflächlicher Harnblasentumoren durch Zytologie, Immunzytologie und Flowzytometrie: Ergebnisse einer prospektiven vergleichenden Studie an 104 Patienten. Akt Urol 19: 13–17CrossRefGoogle Scholar
  12. Huland E, Huland H, Schneider AW (1990) Quantitative immunocytology in the management of patients with superficial bladder carcinoma. I. A marker to identify patients who do not require prophylaxis. J Urol 144: 637–640PubMedGoogle Scholar
  13. Huland E, Huland H, Meier T, Baricordi O, Fradet Y, Grossman HB, Hodges GM, Messing EM, Schmitz-Dräger BJ (1991) Comparison of 15 monoclonal antibodies against tumor-associated antigens of transitional cell carcinoma of the human bladder. J Urol 146: 1631–1636PubMedGoogle Scholar
  14. Huland H, Arndt R, Huland E, Loening TE, Steffens M (1987) Monoclonal antibody 486P3/12: a valuable bladder carcinoma marker for immunocytology. J Urol 137: 654–659PubMedGoogle Scholar
  15. Itzkowitz SH, Yuan M, Fukushi Y, Palekar A, Phelps PC, Shamsuddin AM, Trump BF, Hakomori S, Kim YS (1986) Lewisx-antigen expression in human malignant and nonmalignant colonic tissues. Cancer Res 46: 2627–2632PubMedGoogle Scholar
  16. Klän R, Huland E, Baisch H, Huland H (1991) Sensitivity of urinary quantitative immunocytology with monoclonal antibody 486P3/12 in 241 unselected patients with bladder carcinoma. J Urol 145: 495–497PubMedGoogle Scholar
  17. Köhler G, Milstein C (1975) Continous culture of fused cells secreting antibody of predefined specificity. Nature (London) 256: 495–497CrossRefGoogle Scholar
  18. Koss LG, Deitch D, Ramanathan R, Sherman AB (1985) Diagnostic value of cytology of voided urine. Acta Cytol 29: 810–816PubMedGoogle Scholar
  19. Longin A, Hijazi A, Berger-Dutrieux N, Escourrou G, Bouvier R, Richer G, Mironneau I, Frontaniére B, Devonec M, Laurent JC (1989) A monoclonal antibody (BL2–10D1) reacting with a bladder-cancer associated antigen. Int J Cancer 43: 183–189PubMedCrossRefGoogle Scholar
  20. Longin A, Fontaniére B, Berger-Dutrieux N, Devonec M, Laurent J-C (1990) A useful monoclonal antibody (BL2–10D1) to identify tumor cells in urine cytology. Cancer 65: 1412–1417PubMedCrossRefGoogle Scholar
  21. Rettig WJ, Cordon-Cardo C, Ng JS, Oettgen HF, Old LJ, Lloyd KO (1985) Heigh-molecular-weight glycoproteins of human teratocarcinoma defined by monoclonal antibodies to carbohydrate determinants. Cancer Res 45: 815–822PubMedGoogle Scholar
  22. Schmitz-Dräger BJ, Rohde D, Peschkes C, Ebert T, Ackermann R (1988) Monoklonale Antikörper gegen Harnblasenkarzinome — ein Beitrag zur Verbesserung der Diagnostik? Akt Urol 19: 117–123CrossRefGoogle Scholar
  23. Schmitz-Dräger BJ, Nakamura S, Decken K, Pfitzer P, Rottmann-Ickler C, Ebert T, Ackermann R (1991) Monoclonal antibody Due ABC3 directed against transitional cell carcinoma. II. Prospective trial on the diagnostic value of immunocytology using monoclonal antibody Due ABC3. J Urol 146: 1521–1524PubMedGoogle Scholar
  24. Schmitz-Dräger BJ, Gerke R, Strich WE, Decken K, Ebert T (1994) Filter-Immunzytologie (FLIC) — Ein neuer Test zum Nachweis antigener Veränderungen auf Urothelzellen. In: Jonas U (Hrsg) Jahrbuch der Urologie 1994, 147–149Google Scholar
  25. Sheinfeld J, Reuter VE, Melamed MR, Fair WR, Morse M, Sogani PC, Herr HW, Whitmore WF, Cordon-Cardo C (1990) Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol 143: 285–288PubMedGoogle Scholar
  26. Shibayama T, Decken K, Bojar H, Severin M, Ebert T, Ackermann R, Schmitz-Dräger BJ (1994) Untersuchungen zur antikörpergestützten Zweiparameter-Durchflußzytometrie in der Diagnostik von Urotheltumoren. Akt Urol 25: 237–242CrossRefGoogle Scholar
  27. Walker KZ, Russell PJ, Kingsley EA, Philips J, Raghavan D (1989) Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J Urol 142: 1578–1583PubMedGoogle Scholar
  28. Zein T, Wajsman Z, Englander LS, Gamarra M, Lopez C, Huben RP, Pontes JE (1984) Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa. J Urol 132: 670–671PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • B. J. Schmitz-Dräger

There are no affiliations available

Personalised recommendations